mRNA EBV vaccine in healthy young adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, dose-escalation trial evaluates the safety, tolerability, and immune response of VXCO-102 against Epstein-Barr virus in healthy young adults. Participants are recruited at multiple sites in Australia and receive VXCO-102 or placebo with a booster at week 8 after a sentinel safety check in each dose cohort. Up to 90 individuals will be enrolled, monitored through clinical assessments, lab tests, and adverse event reporting. The study includes strict exclusion criteria to minimize risk, including recent vaccination history and potential pregnancy. Primary aims focus on safety and immunogenicity rather than efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 to 25 years, inclusive
* Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment

Exclusion Criteria:

* Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation
* Likely or confirmed myocarditis or pericarditis
* Prior receipt of an investigational EBV vaccine
* Prior receipt of a licensed vaccine within 56 days prior to Day 1
* Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study.
* For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study

Note: Other inclusion and exclusion criteria apply.

Where it's running

• Q-Pharm Pty Ltd/Nucleus Network Pty Ltd
  Herston, Queensland, Australia Recruiting
• Nucleus Network Pty Ltd
  Melbourne, Victoria, Australia Recruiting

Study contacts

• Study coordinator: Christina Chang
• Email: melbourne@nucleusnetwork.com
• Phone: (+61) 3 8593 9801

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Golidocitinib plus selinexor for chronic active Epstein‑Barr virus disease (CAEBVD)

  This trial will try combining golidocitinib and selinexor to treat adults aged 18–70 with chronic active Epstein‑Barr virus disease, including EBV‑associated lymphohistiocytosis.

  Recruiting Phase 2/3 Beijing Friendship Hospital · Beijing · NCT07369739

• Vaccination against Epstein-Barr Virus in Healthy Adults

  This study is testing two new vaccines for the Epstein-Barr Virus in healthy adults aged 18 to 29 to see if they can safely boost the immune response against the virus.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06908096

• Infusing donor-derived virus-specific T-cells to treat post-transplant viral infections

  This study is testing if infusing special immune cells from donors can help patients who have had a stem cell transplant and are struggling with tough viral infections.

  Recruiting Phase 2 University Hospital, Basel, Switzerland · Basel · NCT02007356

• Understanding severe viral infections in patients without known immune issues

  This study is trying to understand why some healthy people get severe viral infections and how different tests can help figure it out.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01011712

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.